Synopsis
Synopsis
0
VMF
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Anhydrous Ceftriaxone Sodium
2. Benaxona
3. Cefatriaxone
4. Cefaxona
5. Ceftrex
6. Ceftriaxon
7. Ceftriaxon Curamed
8. Ceftriaxon Hexal
9. Ceftriaxona Andreu
10. Ceftriaxona Ldp Torlan
11. Ceftriaxone
12. Ceftriaxone Irex
13. Ceftriaxone Sodium
14. Ceftriaxone Sodium, Anhydrous
15. Ceftriaxone, Disodium Salt
16. Ceftriaxone, Disodium Salt, Hemiheptahydrate
17. Lendacin
18. Longacef
19. Longaceph
20. Ro 13 9904
21. Ro 13-9904
22. Ro 139904
23. Ro-13-9904
24. Ro13 9904
25. Ro13-9904
26. Ro139904
27. Rocefalin
28. Rocefin
29. Rocephin
30. Rocephine
31. Tacex
32. Terbac
1. Ceftriaxone Sodium
2. Ceftriaxone
3. 74578-69-1
4. 104376-79-6
5. Ro-139904
6. Ceftriaxone Sodium Salt
7. Octx
8. Ceftriaxone Sodium Trihydrate
9. Schembl537013
10. Chembl1200995
11. Mfcd00941454
12. Akos015961150
13. Ac-1851
14. Disodium;(6r,7r)-7-[[(2e)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-6-oxido-5-oxo-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
15. Sodium (6r,7r)-7-((e)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-3-((6-hydroxy-2-methyl-5-oxo-2,5-dihydro-1,2,4-triazin-3-ylthio)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
16. Sodium;(6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-5,6-dioxo-1h-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
| Molecular Weight | 576.6 g/mol |
|---|---|
| Molecular Formula | C18H17N8NaO7S3 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 13 |
| Rotatable Bond Count | 8 |
| Exact Mass | 576.02800271 g/mol |
| Monoisotopic Mass | 576.02800271 g/mol |
| Topological Polar Surface Area | 291 Ų |
| Heavy Atom Count | 37 |
| Formal Charge | 0 |
| Complexity | 1120 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 2 | |
|---|---|
| Drug Name | Rocephin |
| PubMed Health | Ceftriaxone (Injection) |
| Drug Classes | Antibiotic |
| Drug Label | Rocephin is a sterile, semisynthetic, broad-spectrum cephalosporin antibiotic for intravenous or intramuscular administration. Ceftriaxone sodium is (6R,7R)-7-[2-(2-Amino-4-thiazolyl)glyoxylamido]-8-oxo-3-[[(1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-as-t... |
| Active Ingredient | Ceftriaxone sodium |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 500mg base/vial; eq 1gm base/vial |
| Market Status | Prescription |
| Company | Hoffmann La Roche |
| 2 of 2 | |
|---|---|
| Drug Name | Rocephin |
| PubMed Health | Ceftriaxone (Injection) |
| Drug Classes | Antibiotic |
| Drug Label | Rocephin is a sterile, semisynthetic, broad-spectrum cephalosporin antibiotic for intravenous or intramuscular administration. Ceftriaxone sodium is (6R,7R)-7-[2-(2-Amino-4-thiazolyl)glyoxylamido]-8-oxo-3-[[(1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-as-t... |
| Active Ingredient | Ceftriaxone sodium |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 500mg base/vial; eq 1gm base/vial |
| Market Status | Prescription |
| Company | Hoffmann La Roche |
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
J - Antiinfectives for systemic use
J01 - Antibacterials for systemic use
J01D - Other beta-lactam antibacterials
J01DD - Third-generation cephalosporins
J01DD04 - Ceftriaxone
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
GDUFA
DMF Review : Complete
Rev. Date : 2013-03-07
Pay. Date : 2013-02-21
DMF Number : 17541
Submission : 2004-07-01
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 17259
Submission : 2004-03-25
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 17824
Submission : 2004-10-30
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13656
Submission : 1998-09-01
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 17884
Submission : 2004-12-04
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 15931
Submission : 2002-03-26
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 17714
Submission : 2004-09-29
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 17257
Submission : 2004-03-30
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 16467
Submission : 2003-03-12
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 4996
Submission : 1983-06-21
Status : Active
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
Ceftriaxone Sodium, Sterile And Bacterial Endoto...
Certificate Number : R1-CEP 2003-169 - Rev 01
Status : Valid
Issue Date : 2011-02-18
Type : Chemical
Substance Number : 991
Certificate Number : R1-CEP 2005-189 - Rev 00
Status : Withdrawn by Holder
Issue Date : 2013-10-09
Type : Chemical
Substance Number : 991
Ceftriaxone Sodium, Sterile, Process T
Certificate Number : R0-CEP 2001-087 - Rev 01
Status : Expired
Issue Date : 2004-07-29
Type : Chemical
Substance Number : 991
Certificate Number : R1-CEP 2001-084 - Rev 01
Status : Valid
Issue Date : 2008-05-06
Type : Chemical
Substance Number : 991
Ceftriaxone Sodium, Sterile; Process A
Certificate Number : R1-CEP 1998-013 - Rev 02
Status : Withdrawn by Holder
Issue Date : 2004-11-12
Type : Chemical
Substance Number : 991
Certificate Number : R0-CEP 2001-222 - Rev 02
Status : Expired
Issue Date : 2005-08-22
Type : Chemical
Substance Number : 991
Certificate Number : R1-CEP 2000-017 - Rev 00
Status : Withdrawn by EDQM Failure to CEP pro...
Issue Date : 2007-05-29
Type : Chemical
Substance Number : 991
Certificate Number : R0-CEP 2003-214 - Rev 00
Status : Expired
Issue Date : 2005-01-26
Type : Chemical
Substance Number : 991
Certificate Number : R1-CEP 2004-137 - Rev 04
Status : Valid
Issue Date : 2016-09-02
Type : Chemical
Substance Number : 991
Certificate Number : R1-CEP 1999-192 - Rev 05
Status : Valid
Issue Date : 2018-02-16
Type : Chemical
Substance Number : 991
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
Details:
Through this MOU, the parties will seek to collaborate on efforts to determine market potential for zoliflodacin, therapeutic value to patients and explore possibilities to enter into future manufacturing and supply agreements.
Lead Product(s): Zoliflodacin,Azithromycin,Ceftriaxone
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: The Global Antibiotic Research and Development Partnership
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 17, 2020
Lead Product(s) : Zoliflodacin,Azithromycin,Ceftriaxone
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : The Global Antibiotic Research and Development Partnership
Deal Size : Undisclosed
Deal Type : Agreement
GARDP, Dr. Reddy’s and Aurigene Pharmaceutical Services Limited Sign MOU for Antibiotic Access T...
Details : Through this MOU, the parties will seek to collaborate on efforts to determine market potential for zoliflodacin, therapeutic value to patients and explore possibilities to enter into future manufacturing and supply agreements.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 17, 2020
Details:
Zoliflodacin, an antibiotic, is currently undergoing evaluation in late-stage clinical trials with patients for treating gonorrhea, in combination with ceftriaxone/azithromycin.
Lead Product(s): Zoliflodacin,Azithromycin,Ceftriaxone
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 24, 2024
Lead Product(s) : Zoliflodacin,Azithromycin,Ceftriaxone
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Innoviva’s Zoliflodacin Phase 3 Data in Uncomplicated Gonorrhea Announced at ESCMID 2024
Details : Zoliflodacin, an antibiotic, is currently undergoing evaluation in late-stage clinical trials with patients for treating gonorrhea, in combination with ceftriaxone/azithromycin.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 24, 2024
Details:
Elores, a cutting-edge antibiotic novel combination of Ceftriaxone (third generation beta-lactam cephalosporin), Sulbactam (beta-lactamase inhibitor) and Disodium EDTA (Class 1 Antibiotic Resistance Breaker) for complicated urinary tract infections.
Lead Product(s): Ceftriaxone,Edetate Calcium Disodium,Sulbactam
Therapeutic Area: Infections and Infectious Diseases Brand Name: Elores
Study Phase: Approved FDFProduct Type: Antibiotic
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 14, 2023
Lead Product(s) : Ceftriaxone,Edetate Calcium Disodium,Sulbactam
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Venus Remedies Expands Reach with the Launch of Elores in Ecuador
Details : Elores, a cutting-edge antibiotic novel combination of Ceftriaxone (third generation beta-lactam cephalosporin), Sulbactam (beta-lactamase inhibitor) and Disodium EDTA (Class 1 Antibiotic Resistance Breaker) for complicated urinary tract infections.
Product Name : Elores
Product Type : Antibiotic
Upfront Cash : Inapplicable
October 14, 2023
Details:
Under the agreement, Hasten acquired Roche's China mainland rights for Rocephin® (ceftriaxone sodium), a long-acting, broad spectrum cephalosporin antibiotic, including the product's marketing authorization and certain intellectual property, including trademarks.
Lead Product(s): Ceftriaxone
Therapeutic Area: Infections and Infectious Diseases Brand Name: Rocephin
Study Phase: Approved FDFProduct Type: Antibiotic
Sponsor: Hasten Biopharmaceutic
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition April 05, 2023
Lead Product(s) : Ceftriaxone
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Hasten Biopharmaceutic
Deal Size : Undisclosed
Deal Type : Acquisition
Hasten Acquires Commercial Rights In China For Roche’s Antibiotic Rocephin®
Details : Under the agreement, Hasten acquired Roche's China mainland rights for Rocephin® (ceftriaxone sodium), a long-acting, broad spectrum cephalosporin antibiotic, including the product's marketing authorization and certain intellectual property, including t...
Product Name : Rocephin
Product Type : Antibiotic
Upfront Cash : Undisclosed
April 05, 2023
Details:
Through this MOU, the parties will seek to collaborate on efforts to determine market potential for zoliflodacin, therapeutic value to patients and explore possibilities to enter into future manufacturing and supply agreements.
Lead Product(s): Zoliflodacin,Azithromycin,Ceftriaxone
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: The Global Antibiotic Research and Development Partnership
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 17, 2020
Lead Product(s) : Zoliflodacin,Azithromycin,Ceftriaxone
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : The Global Antibiotic Research and Development Partnership
Deal Size : Undisclosed
Deal Type : Agreement
GARDP, Dr. Reddy’s and Aurigene Pharmaceutical Services Limited Sign MOU for Antibiotic Access T...
Details : Through this MOU, the parties will seek to collaborate on efforts to determine market potential for zoliflodacin, therapeutic value to patients and explore possibilities to enter into future manufacturing and supply agreements.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 17, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Excipients by Applications
Parenteral
Fillers, Diluents & Binders
Digital Content
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
REF. STANDARDS & IMPURITIES
ANALYTICAL
Analytical Methods
ABOUT THIS PAGE
14
PharmaCompass offers a list of Ceftriaxone API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Ceftriaxone manufacturer or Ceftriaxone supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Ceftriaxone manufacturer or Ceftriaxone supplier.
PharmaCompass also assists you with knowing the Ceftriaxone API Price utilized in the formulation of products. Ceftriaxone API Price is not always fixed or binding as the Ceftriaxone Price is obtained through a variety of data sources. The Ceftriaxone Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Roche Brand of Ceftriaxone Sodium manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Roche Brand of Ceftriaxone Sodium, including repackagers and relabelers. The FDA regulates Roche Brand of Ceftriaxone Sodium manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Roche Brand of Ceftriaxone Sodium API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Roche Brand of Ceftriaxone Sodium manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Roche Brand of Ceftriaxone Sodium supplier is an individual or a company that provides Roche Brand of Ceftriaxone Sodium active pharmaceutical ingredient (API) or Roche Brand of Ceftriaxone Sodium finished formulations upon request. The Roche Brand of Ceftriaxone Sodium suppliers may include Roche Brand of Ceftriaxone Sodium API manufacturers, exporters, distributors and traders.
click here to find a list of Roche Brand of Ceftriaxone Sodium suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Roche Brand of Ceftriaxone Sodium DMF (Drug Master File) is a document detailing the whole manufacturing process of Roche Brand of Ceftriaxone Sodium active pharmaceutical ingredient (API) in detail. Different forms of Roche Brand of Ceftriaxone Sodium DMFs exist exist since differing nations have different regulations, such as Roche Brand of Ceftriaxone Sodium USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Roche Brand of Ceftriaxone Sodium DMF submitted to regulatory agencies in the US is known as a USDMF. Roche Brand of Ceftriaxone Sodium USDMF includes data on Roche Brand of Ceftriaxone Sodium's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Roche Brand of Ceftriaxone Sodium USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Roche Brand of Ceftriaxone Sodium suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Roche Brand of Ceftriaxone Sodium Drug Master File in Japan (Roche Brand of Ceftriaxone Sodium JDMF) empowers Roche Brand of Ceftriaxone Sodium API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Roche Brand of Ceftriaxone Sodium JDMF during the approval evaluation for pharmaceutical products. At the time of Roche Brand of Ceftriaxone Sodium JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Roche Brand of Ceftriaxone Sodium suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Roche Brand of Ceftriaxone Sodium Drug Master File in Korea (Roche Brand of Ceftriaxone Sodium KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Roche Brand of Ceftriaxone Sodium. The MFDS reviews the Roche Brand of Ceftriaxone Sodium KDMF as part of the drug registration process and uses the information provided in the Roche Brand of Ceftriaxone Sodium KDMF to evaluate the safety and efficacy of the drug.
After submitting a Roche Brand of Ceftriaxone Sodium KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Roche Brand of Ceftriaxone Sodium API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Roche Brand of Ceftriaxone Sodium suppliers with KDMF on PharmaCompass.
A Roche Brand of Ceftriaxone Sodium CEP of the European Pharmacopoeia monograph is often referred to as a Roche Brand of Ceftriaxone Sodium Certificate of Suitability (COS). The purpose of a Roche Brand of Ceftriaxone Sodium CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Roche Brand of Ceftriaxone Sodium EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Roche Brand of Ceftriaxone Sodium to their clients by showing that a Roche Brand of Ceftriaxone Sodium CEP has been issued for it. The manufacturer submits a Roche Brand of Ceftriaxone Sodium CEP (COS) as part of the market authorization procedure, and it takes on the role of a Roche Brand of Ceftriaxone Sodium CEP holder for the record. Additionally, the data presented in the Roche Brand of Ceftriaxone Sodium CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Roche Brand of Ceftriaxone Sodium DMF.
A Roche Brand of Ceftriaxone Sodium CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Roche Brand of Ceftriaxone Sodium CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Roche Brand of Ceftriaxone Sodium suppliers with CEP (COS) on PharmaCompass.
A Roche Brand of Ceftriaxone Sodium written confirmation (Roche Brand of Ceftriaxone Sodium WC) is an official document issued by a regulatory agency to a Roche Brand of Ceftriaxone Sodium manufacturer, verifying that the manufacturing facility of a Roche Brand of Ceftriaxone Sodium active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Roche Brand of Ceftriaxone Sodium APIs or Roche Brand of Ceftriaxone Sodium finished pharmaceutical products to another nation, regulatory agencies frequently require a Roche Brand of Ceftriaxone Sodium WC (written confirmation) as part of the regulatory process.
click here to find a list of Roche Brand of Ceftriaxone Sodium suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Roche Brand of Ceftriaxone Sodium as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Roche Brand of Ceftriaxone Sodium API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Roche Brand of Ceftriaxone Sodium as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Roche Brand of Ceftriaxone Sodium and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Roche Brand of Ceftriaxone Sodium NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Roche Brand of Ceftriaxone Sodium suppliers with NDC on PharmaCompass.
Roche Brand of Ceftriaxone Sodium Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Roche Brand of Ceftriaxone Sodium GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Roche Brand of Ceftriaxone Sodium GMP manufacturer or Roche Brand of Ceftriaxone Sodium GMP API supplier for your needs.
A Roche Brand of Ceftriaxone Sodium CoA (Certificate of Analysis) is a formal document that attests to Roche Brand of Ceftriaxone Sodium's compliance with Roche Brand of Ceftriaxone Sodium specifications and serves as a tool for batch-level quality control.
Roche Brand of Ceftriaxone Sodium CoA mostly includes findings from lab analyses of a specific batch. For each Roche Brand of Ceftriaxone Sodium CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Roche Brand of Ceftriaxone Sodium may be tested according to a variety of international standards, such as European Pharmacopoeia (Roche Brand of Ceftriaxone Sodium EP), Roche Brand of Ceftriaxone Sodium JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Roche Brand of Ceftriaxone Sodium USP).
